Marc Le Bozec

BioProtein Technologies SA develops recombinant therapeutic proteins and vaccines. Its proprietary technology offers customized packages supplying highly purified biopharmaceuticals. The firm provides pharmaceutical and biotechnology companies with integrated services from gene expression to industrial production of proteins and vaccines in milk. The company was founded on July 1, 1988 by Marc Le Bozec, Louis-Marie Houdebine, Jean-Paul Renard, Bernard Jégou and François Deneux and is headquartered in Jouy-en-Josas, France.

Takara Bio Europe AB is a provider of stem cell derived products and technologies which will drive unprecedented innovation in drug discovery and regenerative medicine today and in the future. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools. Cellartis is also the single commercial source of ethically derived hES cell lines and has developed cell lines for a range of uses. This hES cell technology platform offers a path to tools and regenerative medicine discoveries of the future. The company was founded in 2001 and is headquartered in Gothenburg, Sweden.

CYTOO SA operates as a contract research organization which develops physiological cell-based assays. It focuses on developing, manufacturing, and commercializing new technologies for cell analysis for life sciences research community. The company has offices in Bethesda and Grenoble. The company was founded by François Chatelain, Alexandra Fuchs and Jacques Lewiner in 2008 and is headquartered in Grenoble, France.

France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.

Financière Arbevel SA is an independent asset management firm headquartered in Paris, France. The firm was founded in 1997 and manages small and medium-sized French and European funds. Financière Arbevel is a socially responsible investor and signatory to the UN Principles for Responsible Investment (UNPRI) which integrates environmental, social, and governance considerations into their investment process.

NH TherAguix SAS operates as a biotechnology company. The firm develops a nanodrug against cancer called AGuIX based on nanometric structuring that allows intravenous injection and the combination of the following properties to fight tumors: targeting, imaging, and treating. The company was founded by G?raldine Le Duc, Olivier Tillement and Fran?ois Lux in on December 11, 2015 and is headquartered in Meylan, France.

Mexbrain SAS is a French company that specializes in increasing the efficiency of treatment by combining the best of both worlds. The company is based in Fontaines-Saint-Martin, France. Mexbrain invites interested parties to contact them for any questions or investment opportunities. However, Thomas Brichart has been the CEO since incorporation.

Clevexel Pharma SAS manufactures as well as distributes pharmaceutical products. It engages in biotechnological research. The company was founded by Christian Bloy, Xiuping Wang-Zhang and Laurent Benel in 2012 and is headquartered in Paris, France.